Posting of Annual Report & Notice of AGM

Tissue Regenix

27/06/2025 07:00

RNS Number : 6374O

Tissue Regenix Group PLC

27 June 2025

 

Tissue Regenix Group plc

('Tissue Regenix', the 'Group' or the 'Company')

 

Posting of Annual Report & Accounts

Notice of AGM

 

Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company, announces that the Annual Report and Accounts, notice of AGM, will be available later this morning on the Company's website, www.tissueregenix.com, in accordance with AIM Rule 20. For those who opted to receive hard copies of the Annual Report, these will be posted today.

 

The Company's AGM will be held at DLA Piper UK LLP, City Square House, 11 Wellington St, Leeds LS1 4DL on 23 July 2025 at 1:00pm (BST). Shareholders are invited to ask the Board questions about the Annual Report and Accounts or the AGM by email emailing Walbrook PR at TissueRegenix@walbrookpr.com. 

 

The results of the votes on the proposed resolutions will be announced by RNS as soon as practicable after the conclusion of the AGM.

 

Investor Briefing

Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, will host a live online presentation relating to the final results via the Investor Meet Company platform at 2pm (BST) on Tuesday 1 July 2025. The presentation is open to all existing and potential shareholders.

 

Investors can sign up to Investor Meet Company for free and register for the presentation here:  

https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor

 

 

For more information, please contact:

 

Tissue Regenix Group plc
Daniel Lee, Chief Executive Officer
David Cocke, Chief Financial Officer
via Walbrook PR
Cavendish Capital Markets (Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Edward Whiley
Nigel Birks - Life Science Specialist Sales
Harriet Ward - ECM
Tel: +44 (0) 20 7466 5000
Walbrook PR (Financial PR and IR)
Tel: +44 (0)20 7933 8780
Alice Woodings / Lianne Applegarth
Tissue Regenix@walbrookpr.com

 

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold that is not rejected by the patient's body and can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NOAUNRNRVKUNUAR